These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24634380)

  • 1. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
    Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
    Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.
    Matsuo K; Nishimura M; Komurov K; Shahzad MM; Ali-Fehmi R; Roh JW; Lu C; Cody DD; Ram PT; Loizos N; Coleman RL; Sood AK
    Gynecol Oncol; 2014 Jan; 132(1):166-75. PubMed ID: 24183729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
    Russell MR; Liu Q; Fatatis A
    Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
    Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
    Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
    Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
    Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
    Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
    Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
    Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
    Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
    Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
    Thanapprapasr D; Previs RA; Hu W; Ivan C; Armaiz-Pena GN; Dorniak PL; Hansen JM; Rupaimoole R; Huang J; Dalton HJ; Ali-Fehmi R; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Jun; 14(6):1466-1475. PubMed ID: 25833835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α.
    Nayeem MJ; Yamamura A; Hayashi H; Muramatsu H; Nakamura K; Sassa N; Sato M
    Life Sci; 2022 Jan; 288():120171. PubMed ID: 34822800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
    Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
    Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
    Chen S; Yao L
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
    Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.